Although the PrRP-GPR10 system might constitute an attractive therapeutic target in obesity treatment, the short plasma half-life of PrRP20 and PrRP31 prevents the potential use of these neuropeptides6,8,21–23. This evidence concerns the gene PRLHR and obesity disorder.